Autolus Therapeutics plc
Autolus Therapeutics plc (AUTL) Revenue
Annual & quarterly revenue history · segment & region breakdown
AUTL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAutolus Therapeutics plc trailing twelve-month (TTM) revenue is $0.09B, an increase of 646.68% year-over-year from $0.08B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.08B | +$0.07B | +646.68% |
| 2024-12-31 | $0.01B | +$0.01B | +496.00% |
| 2023-12-31 | $0.00B | -$0.00B | -72.59% |
| 2022-12-31 | $0.01B | +$0.00B | +311.02% |
| 2021-12-31 | $0.00B | -$0.00B | -12.13% |
| 2020-12-31 | $0.00B | -$0.00B | -41.02% |
| 2019-12-31 | $0.00B | +$0.00B | +178.19% |
| 2018-09-30 | $0.00B | -$0.00B | -38.25% |
| 2017-09-30 | $0.00B | +$0.00B | +39.69% |
| 2016-09-30 | $0.00B | +$0.00B | +1187.83% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Autolus Therapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Autolus Therapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Autolus Therapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AUTL revenue · 4 questionsAUTL's trailing twelve-month (TTM) revenue is $0.09B. That is an increase of 646.68% year-over-year from $0.08B in FY2025.
▸ Source: FMP · Autolus Therapeutics plc SEC filings · GAAP · Autolus Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026